The Covid-19 vaccine developed by British drugmaker AstraZeneca Plc and Oxford University will likely be authorized for emergency use in the United States in April 2021, the chief adviser for the U.S. Covid-19 vaccine program said.
Operation Warp Speed – the Trump administration’s program to accelerate Covid-19 vaccine development and distribution – succeeded on the development component, but is failing in the early stages of distribution.
The United States Department of Defense (DOD) awarded Moderna a contract valued at $1,966,598,000 for an additional 100 million doses of the company’s Covid-19 vaccine.
A vaccine being developed by the Nanovaccine Institute at Iowa State University (ISU) will be able to be administered without needles and in one dose.
Millions of Covid-19 vaccines were sitting unused in U.S. hospitals and elsewhere a week into the massive inoculation campaign, putting the government’s target for 20 million vaccinations during December in doubt.
The first injections of Moderna’s Covid-19 vaccine started to be administered on Dec. 21 after the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) on Dec. 18.
The first days of Pfizer Inc.’s Covid-19 vaccine rollout have seen unexpected hitches including some vaccines being stored at excessively cold temperatures and Pfizer reporting potential challenges in vaccine production, U.S. officials said.
Daily U.S. deaths from Covid-19 surpassed 3,000 for the third time in a week as the country expanded its vaccination program and Congress progressed toward approving financial relief for pandemic-stricken America.
An intensive care unit nurse became the first person in New York state to receive the Pfizer/BioNTech Covid-19 vaccine on Dec. 14, marking a pivotal turn in the U.S. effort to control the deadly virus.
The first shipments of Covid-19 vaccine left on trucks and planes early on Dec. 13, kicking off a historic effort to stop a surging pandemic that is claiming more than 2,400 lives a day in the United States.
